Company profile
Savara Inc.
NASDAQ: SVRA · Healthcare · Biotechnology
PublicHQ Langhorne, TXCIK 0001160308Reports USD
#984 of 1,418 Healthcare companies by revenue
EA Score
50DFH 39DQ 63GM —SS 61
v0.1 · 55/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$118.8M
Employees
70
as of 2026-08-10
Market cap
$1.2B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$257.0k$257.0k2020
Net income-$118.8M-$118.8M2025
Operating income-$123.5M-$123.5M2025
Total assets$253.4M$253.4M2025
Liabilities$50.3M$50.3M2025
Equity$203.1M$203.1M2025
Revenue trend
FY2013 – FY2020 · USD
FY13
FY14
FY15
FY16
FY16
FY17
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Savara Inc.’s revenue?
Savara Inc. booked $257.0k in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -46240.1% net margin.
Peers · Healthcare
CEL-SCI Corporation32DNutra Pharma Corp.30DNewCardio, Inc.——Nexteligent Holdings, Inc.46DAdhera Therapeutics Inc——Bluejay Diagnostics, Inc.33DKey facts
CEOMatthew Pauls
SectorHealthcare
IndustryBiotechnology
HeadquartersLanghorne, TX
ExchangeNASDAQ: SVRA
Employees70
IPO date2017-04-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.